SCHEMBL4152716

SCHEMBL4152716

Cc1nc(-c2cccc(OCc3ccccc3)c2F)n(CCc2ccccc2)c(=O)c1N=C(c1ccccc1)c1ccccc1

nearest known ligand 0.47

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
CASR P41180 18/20 0.47
NR1I2 O75469 5/20 0.47
PTGER1 P34995 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4138257 0.93 CASR (0.50) CASRNR1I2PTGER1
SCHEMBL14535978 0.84 CASR (0.39) CASRNR1I2PTGER1
SCHEMBL4148597 0.82 CASR (0.49) CASRNR1I2
SCHEMBL4138596 0.82 CASR (0.51) CASRNR1I2
SCHEMBL4143961 0.81 CASR (0.48) CASRNR1I2
SCHEMBL28148354 0.74 CASR (0.55) CASRNR1I2PTGER1
SCHEMBL4143109 0.74 CASR (0.54) CASRNR1I2
SCHEMBL4145053 0.74 CASR (0.57) CASRNR1I2
SCHEMBL4139326 0.74 CASR (0.54) CASRNR1I2
SCHEMBL4138583 0.73 CASR (0.56) CASRNR1I2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090137557-A1 Calcilytic Compounds SMITHKLINE BEECHAM CORPORATION 2009-05-28 US disclosed
US-20090137557-A1 Calcilytic Compounds SMITHKLINE BEECHAM CORPORATION 2009-05-28 US disclosed
US-20090137557-A1 Calcilytic Compounds SMITHKLINE BEECHAM CORPORATION 2009-05-28 US disclosed
EP-1951244-A2 CALCILYTIC COMPOUNDS SmithKline Beecham Corporation (US) 2008-08-06 EP disclosed
WO-2007062370-A2 CALCILYTIC COMPOUNDS SMITHKLINE BEECHAM CORPORATION (US) 2007-05-31 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090137557-A1 Calcilytic Compounds CALCR, SOST, CALCB CASR 12/4885NR1I2 3373/4885PTGER1 2958/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.